Linkage Biosciences said this week that it has closed a Series B financing round worth $2 million.
Linkage markets the LinkSeq HLA product line, which uses a proprietary software and chemistry platform in conjunction with real-time PCR instrumentation for HLA typing. According to the company, LinkSeq is an end-point PCR process that uses allele-specific amplification combined with SYBR Green to detect PCR products on the instrument using melt-curve analysis.
Fisher Capital and Greenhouse Capital Partners led the Series B round, which follows $2 million in Series A financing that the company raised in 2009 and $1 million in venture financing from Greenhouse Capital in 2007.
Linkage said it will use the funds to expand its manufacturing capabilities, complete regulatory requirements in the US and Europe, and accelerate the development of additional molecular tests.